- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03595904
Internet-Based Motivational Interviewing for Colonoscopy
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Colorectal cancer (CRC), a largely preventable disease, remains the third leading cause of cancer death in the United States. Compared to other racial groups, African Americans have the highest CRC morbidity and mortality rates. Recent reports have found that African Americans' CRC incidence rates are 20% higher and mortality rates are 45% higher than those of whites. Given these disparities, it is critical to increase African Americans' participation in CRC screenings. Of the recommended CRC screening mechanisms, a colonoscopy is often the preferred method because it allows for both the detection and removal of precancerous and cancerous polyps. Although screening colonoscopies can detect and prevent CRC, more than 1/3 of African Americans have not received a screening colonoscopy within the recommended time frame (one screening colonoscopy per ten years). It is critical to increase African Americans' screening colonoscopy rates in order to reduce racial inequities in CRC morbidity and mortality.
A motivational interviewing (MI) intervention can help improve African Americans' screening colonoscopy uptake. MI is a brief patient-centered intervention that increases perceived competence, autonomy, and relatedness in order to promote behavioral change. Extensive research supports the efficacy of MI to promote preventive health screening uptake, including increasing screening colonoscopy rates, and MI has proven efficacious with African Americans across a wide range of diseases.
Traditionally, MI is delivered live, where individuals meet with a professional for a one-on-one intervention. Although efficacious, live-MI is not without limitations. Of greatest concern, live-MI requires both staffing and economic resources, limiting its ability to be widely disseminated. A digital intervention, such a tablet app, may overcome these limitations. By eliminating the need for an on-site professional, a tablet app is a high reach, low cost intervention with the potential to have a significant public health impact.
The primary goal of this study is to conduct a randomized clinical trial (RCT) that examines the efficacy of a tablet app, called e-Motivate, to improve screening colonoscopy rates in African Americans.
The app first underwent iterative field-testing and subsequent modifications to ensure that the app had high usability and acceptability ratings.
The final version of the app, called e-Motivate, will be tested in a randomized clinical trial. African American patients referred for a screening colonoscopy will be recruited to the RCT. Participants (N=200) will be randomly assigned to a usual care group (N=100) or an e-Motivate group (N=100). Participants in the usual care group will receive standard patient navigation (e.g., scheduling, reminder calls). Participants in the e-Motivate group will receive standard clinical care and will also complete the e-Motivate app. The app will be a 20-minute tablet app that will include motivational interviewing informed exercises and education. The app will be completed in the clinic immediately after a participant receives a referral for a screening colonoscopy. Six months following the initial referral, participants medical charts will be reviewed to determine whether they completed the recommended screening colonoscopy. It is hypothesized that participants in the e-Motivate group will be more likely to complete the recommended screening colonoscopy.
The study will also explore whether the e-Motivate app can improve secondary outcomes (e.g., bowel prep quality, number of cancellations).
Potential mediators, informed by Self Determination Theory, will be evaluated. Potential moderators (e.g., age, education, family history of CRC) will be explored.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10029
- Icahn School of Medicine at Mount Sinai and Mount Sinai Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- self-identified as African American/Black
- received a referral for a screening colonoscopy
- recommended age to begin screening for colorectal cancer (based on current guidelines)
- English speaking
Exclusion Criteria:
- hearing or vision impaired
- participated in the previous iterative field testing
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: E-Motivate group
Participants complete a 20-minute tablet app, called e-Motivate, and receive usual care.
|
Participants in the e-Motivate group will receive standard clinical care which includes patient navigation (e.g., scheduling and reminders).
They will also complete a 20-minute, motivational interviewing informed tablet app in the clinic immediately after they receive a referral for a screening colonoscopy.
The tablet app consists of educational videos, interactive exercises (e.g., decisional balance), and personalized feedback (e.g., print summary).
|
|
Active Comparator: Usual Care Group
Participants in the usual care group will receive standard clinical care for patients referred for a screening colonoscopy
|
Participants in the usual care group will receive standard clinical care for patients referred for a screening colonoscopy.
In particular, they will receive patient navigation which includes scheduling the colonoscopy appointment, making reminder calls, and providing print materials regarding the bowel prep instructions.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Participants Who Completed a Screening Colonoscopy
Time Frame: six months after the initial referral
|
Six months following the initial referral, medical charts was reviewed to determine whether the participant completed the recommended screening colonoscopy
|
six months after the initial referral
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Participants With Adequate Bowel Prep Quality
Time Frame: six months after initial referral
|
An adequate prep which is defined as "adequate, excellent or good".
An inadequate prep would be defined as "inadequate, poor or fair".
Six months following the initial referral, medical charts was reviewed to determine the physician-rated bowel prep quality for participants who completed the screening colonoscopy.
|
six months after initial referral
|
|
Number of Participants Who Had Canceled Appointments
Time Frame: six months
|
Process variable was assessed via medical chart review six months following the initial referral
|
six months
|
|
Number of Patients Who Had Rescheduled Appointments
Time Frame: six months
|
Process variable was assessed via medical chart review six months following the initial referral
|
six months
|
|
Number of Participants Who Were No-show Appointments
Time Frame: six months
|
Process variable was assessed via medical chart review six months following the initial referral
|
six months
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Sarah Miller, PsyD, Icahn School of Medicine at Mount Sinai and Mount Sinai Hospital
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- GCO 14-0275
- K07CA190726 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Colorectal Neoplasms
-
City of Hope Medical CenterRecruitingColorectal Neoplasms | Colorectal Cancer | Colorectal Adenocarcinoma | Colorectal Cancer Stage II | Colorectal Cancer Stage III | Colorectal Cancer Stage IV | Colorectal Neoplasms Malignant | Colorectal Cancer Stage IUnited States, Japan, Italy, Spain
-
Emory UniversityBristol-Myers Squibb; National Cancer Institute (NCI); National Institutes of...CompletedColorectal Cancer Metastatic | Colorectal Adenocarcinoma | Stage IV Colorectal Cancer | Stage IVA Colorectal Cancer | Stage IVB Colorectal Cancer | Refractory Colorectal Carcinoma | Metastatic Microsatellite Stable Colorectal Carcinoma | Stage IVC Colorectal CancerUnited States
-
NuCana plcCompletedColorectal Neoplasms | Colorectal Cancer | Colorectal Tumors | Colorectal Carcinoma | Neoplasms, ColorectalUnited States, France, United Kingdom
-
The Queen Elizabeth HospitalNovartis; AmgenCompletedColorectal Cancer | Colorectal Tumors | Colorectal Carcinoma | Neoplasms, ColorectalAustralia
-
Novartis PharmaceuticalsCompletedColorectal Cancer | Colorectal Tumors | Colorectal Carcinoma | Neoplasms, ColorectalUnited States
-
ProgenaBiomeWithdrawnColorectal Neoplasms | Colorectal Cancer | Colorectal Cancer Metastatic | Colorectal Carcinoma | Colorectal Adenocarcinoma | Colorectal SarcomaUnited States
-
University of ChicagoVerastem, Inc.SuspendedColorectal Cancer | Colorectal Cancer Metastatic | Colorectal Adenocarcinoma | Advanced Colorectal Carcinoma | Advanced Colorectal AdenocarcinomaUnited States
-
Bristol-Myers SquibbNovartisCompletedColorectal Cancer | Colorectal Neoplasm | Colorectal Tumors | Colorectal CarcinomaUnited States, Canada, Spain, Argentina, Australia, Belgium, Czechia, Italy, Chile, Germany
-
Pawel KalinskiNational Cancer Institute (NCI)CompletedColorectal Neoplasms | Colorectal Cancer | Colorectal Tumors | Colorectal Carcinoma | Neoplasms, ColorectalUnited States
-
Jeremy MeyerUniversity Hospital, Geneva; Hôpital Fribourgeois; Spital Biel, SwitzerlandNot yet recruitingColorectal Neoplasms | Colorectal Cancer | Colorectal Adenoma | Colorectal Adenocarcinoma | Colorectal Polyp | Colorectal Neoplasms Malignant | Colorectal Neoplasms, Benign
Clinical Trials on E-Motivate group
-
VA Office of Research and DevelopmentMichael E. DeBakey VA Medical Center; Dallas VA Medical CenterRecruitingDepression | Musculoskeletal Pain | Aging | Chronic Back PainUnited States
-
Singapore General HospitalSingapore Institute of Technology; National Neuroscience InstituteRecruitingStroke | Physical InactivitySingapore
-
Universitätsklinikum Hamburg-EppendorfGerman Cancer Research CenterRecruiting
-
Bournemouth UniversityDorset HealthCare University NHS Foundation TrustCompletedEating Disorders
-
University of Nebraska LincolnUniversity of NebraskaCompletedSexual AssaultUnited States
-
Columbia UniversityNational Multiple Sclerosis SocietyCompleted
-
Ankara Children's Health and Diseases Hematology...CompletedInfant | Anesthesia Intubation Complication | NewbornTurkey
-
Texas Tech UniversityMcCormick and Company, Inc.CompletedHypertension | Diet, Healthy | Culinary MedicineUnited States
-
University of Colorado, DenverCenters for Disease Control and Prevention; University of Utah; Colorado Department... and other collaboratorsCompletedAccidental FallsUnited States
-
National Taiwan University HospitalUnknown